Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Sertaconazole is an imidazole antifungal agent.1 It is active against various yeasts, including C. albicans and C. tropicalis, and dermatophytes, including Microsporum, Trichophyton, and Epidermophyton (MICs = 0.35-5.04 and 0.24-2 µg/ml, respectively). Sertaconazole inhibits ergosterol (Item No. 19850) biosynthesis (IC50 = 115 nM) and decreases intracellular ATP levels in a concentration-dependent manner in C. albicans.2,3 Topical application of sertaconazole (1%) reduces ear edema induced by phorbol 12-myristate 13-acetate (TPA; Item No. 10008014), resiniferatoxin, or oxazolone in mouse models of irritant dermatitis, neurogenic dermatitis, and allergic contact hypersensitivity, respectively.4 Sertaconazole also selectively inhibits long-chain acyl-CoA synthetase 4 (ACSL4; IC50 = 0.28 µM) over ACSL3 at 50 µM.5 It inhibits lipid peroxidation and ferroptosis induced by (1S,3R)-RSL3 (Item No. 19288) in LUHMES cells when used at a concentration of 5 µM. Formulations containing sertaconazole have been used in the treatment of interdigital tinea pedis.
WARNING This product is not for human or veterinary use.
1. In vitro activity of sertaconazole. Arzneimittelforschung 42(5A), 699-705 (1992).
2. Direct membrane-
3. Inhibition of ergosterol synthesis by sertaconazole in Candida albicans. Arzneimittelforschung 42(5A), 718-720 (1992).
4. Anti-
5. Repositioning of FDA-